Steven Cohen’s Climb Bio CLYM Stock Holding History

Steven Cohen’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-59,090	Closed	-$405K	–	4698
2026 Q1	$405K	Sell	59,090 -657,590	-92%	-$3.79M	﹤0.01%	3221
2025 Q4	$2.87M	Buy	+716,680	New	+$1.72M	﹤0.01%	2253
2024 Q4	–	Sell	-590,946	Closed	-$3.01M	–	2547
2024 Q3	$3.01M	Buy	+590,946	New	+$4.18M	0.01%	1041
2022 Q2	–	Sell	-142,333	Closed	-$1.19M	–	1690
2022 Q1	$1.19M	Buy	+142,333	New	+$1.33M	﹤0.01%	937

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Steven Cohen's CLYM Position: Q2 2026 in Review

Steven Cohen sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 59,090 shares — an estimated $405K sold.

Steven Cohen first reported a position in CLYM in Q1 2022 and held it in 4 quarters. The position peaked at $3.01M in Q3 2024. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Steven Cohen reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 59,090 Climb Bio shares in Q2 2026, an estimated $405K.
Steven Cohen first reported a position in Climb Bio in Q1 2022 and held it in 4 quarters.
Steven Cohen's Climb Bio position peaked at $3.01M in Q3 2024.
108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.